Drug Topics May 1, 2024
Savings associated with biosimilar uptake are projected to reach $181 billion through 2027.
It’s no secret that medications are expensive. Biologic therapies account for only 2% of drugs on the market, but represent 46% of drug spending.1 Biosimilar medications are an answer to these high costs: As some of the most expensive—and most used—biologic drugs reach the end of their exclusivity window, biosimilars are projected to reach $181 billion in cost savings through 2027, according to Cardinal Health’s 2024 Biosimilars Report.1
“It is more important than ever that all stakeholders of the health care ecosystem understand the significant benefits biosimilars offer to patients, providers, practices, and payers alike, said Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal...
Today's Sponsors
Today's Sponsor